Radioligand Therapy of Prostate Cancer with a Long-lasting PSMA Targeting Agent 90Y-DOTA-EB-MCG

Zhantong Wang, Orit Jacobson, Rui Tian, Ronnie Mease, Dale Kiesewetter, Gang Niu, Martin Gilbert Pomper, Xiaoyuan Chen

Research output: Contribution to journalArticle

Abstract

Several radioligands targeting prostate-specific membrane antigen (PSMA) have been clinically introduced as a new class of radiotheranostics for the treatment of prostate cancer. Among them, (((R)-1-carboxy-2-mcercaptoethyl)carbamoyl)-L-glutamic acid (MCG) has been successfully labeled with radioisotopes for prostate cancer imaging. The aim of this study is to conjugate MCG with an albumin binding moiety to further improve the in vivo pharmacokinetics. Methods: MCG was conjugated with an Evans blue (EB) derivative for albumin binding and a DOTA chelator. PSMA positive (PC3-PIP) and PSMA negative (PC3) cells were used for both in vitro and in vivo studies. Longitudinal PET imaging was performed at 1, 4, 24, and 48 h post injection to evaluate the biodistribution and tumor uptake of 86Y-DOTA-EB-MCG. DOTA-EB-MCG was also labeled with 90Y for radionuclide therapy. Besides tumor growth measurement, tumor response to escalating therapeutic doses were also evaluated by immunohistochemistry and fluorescence microscopy. Results: Based on quantification from 86Y-DOTA-EB-MCG PET images, the tracer uptake in PC3-PIP tumors increased from 22.33 ± 2.39 %ID/g at 1 h post-injection (p.i.), to the peak of 40.40 ± 4.79 %ID/g at 24 h p.i. Administration of 7.4 MBq of 90Y-DOTA-EB-MCG resulted in significant regression of tumor growth in PSMA positive xenografts. No apparent toxicity or body weight loss was observed in all treated mice. Conclusion: Modification of MCG with an Evans blue derivative resulted in a highly efficient prostate cancer targeting agent (EB-MCG), which showed great potential in prostate cancer treatment after being labeled with therapeutic radioisotopes.

Original languageEnglish (US)
JournalBioconjugate Chemistry
DOIs
StateAccepted/In press - Apr 27 2018

Fingerprint

Evans Blue
Antigens
Tumors
Prostatic Neoplasms
Membranes
Radioisotopes
Neoplasms
Derivatives
Therapeutics
Imaging techniques
Injections
Albumins
Pharmacokinetics
Oncology
Fluorescence microscopy
Toxicity
Chelating Agents
Growth
human glutamate carboxypeptidase II
Fluorescence Microscopy

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Cite this

Radioligand Therapy of Prostate Cancer with a Long-lasting PSMA Targeting Agent 90Y-DOTA-EB-MCG. / Wang, Zhantong; Jacobson, Orit; Tian, Rui; Mease, Ronnie; Kiesewetter, Dale; Niu, Gang; Pomper, Martin Gilbert; Chen, Xiaoyuan.

In: Bioconjugate Chemistry, 27.04.2018.

Research output: Contribution to journalArticle

Wang, Zhantong ; Jacobson, Orit ; Tian, Rui ; Mease, Ronnie ; Kiesewetter, Dale ; Niu, Gang ; Pomper, Martin Gilbert ; Chen, Xiaoyuan. / Radioligand Therapy of Prostate Cancer with a Long-lasting PSMA Targeting Agent 90Y-DOTA-EB-MCG. In: Bioconjugate Chemistry. 2018.
@article{356818cbe8d14325a899ae54038786b2,
title = "Radioligand Therapy of Prostate Cancer with a Long-lasting PSMA Targeting Agent 90Y-DOTA-EB-MCG",
abstract = "Several radioligands targeting prostate-specific membrane antigen (PSMA) have been clinically introduced as a new class of radiotheranostics for the treatment of prostate cancer. Among them, (((R)-1-carboxy-2-mcercaptoethyl)carbamoyl)-L-glutamic acid (MCG) has been successfully labeled with radioisotopes for prostate cancer imaging. The aim of this study is to conjugate MCG with an albumin binding moiety to further improve the in vivo pharmacokinetics. Methods: MCG was conjugated with an Evans blue (EB) derivative for albumin binding and a DOTA chelator. PSMA positive (PC3-PIP) and PSMA negative (PC3) cells were used for both in vitro and in vivo studies. Longitudinal PET imaging was performed at 1, 4, 24, and 48 h post injection to evaluate the biodistribution and tumor uptake of 86Y-DOTA-EB-MCG. DOTA-EB-MCG was also labeled with 90Y for radionuclide therapy. Besides tumor growth measurement, tumor response to escalating therapeutic doses were also evaluated by immunohistochemistry and fluorescence microscopy. Results: Based on quantification from 86Y-DOTA-EB-MCG PET images, the tracer uptake in PC3-PIP tumors increased from 22.33 ± 2.39 {\%}ID/g at 1 h post-injection (p.i.), to the peak of 40.40 ± 4.79 {\%}ID/g at 24 h p.i. Administration of 7.4 MBq of 90Y-DOTA-EB-MCG resulted in significant regression of tumor growth in PSMA positive xenografts. No apparent toxicity or body weight loss was observed in all treated mice. Conclusion: Modification of MCG with an Evans blue derivative resulted in a highly efficient prostate cancer targeting agent (EB-MCG), which showed great potential in prostate cancer treatment after being labeled with therapeutic radioisotopes.",
author = "Zhantong Wang and Orit Jacobson and Rui Tian and Ronnie Mease and Dale Kiesewetter and Gang Niu and Pomper, {Martin Gilbert} and Xiaoyuan Chen",
year = "2018",
month = "4",
day = "27",
doi = "10.1021/acs.bioconjchem.8b00292",
language = "English (US)",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Radioligand Therapy of Prostate Cancer with a Long-lasting PSMA Targeting Agent 90Y-DOTA-EB-MCG

AU - Wang, Zhantong

AU - Jacobson, Orit

AU - Tian, Rui

AU - Mease, Ronnie

AU - Kiesewetter, Dale

AU - Niu, Gang

AU - Pomper, Martin Gilbert

AU - Chen, Xiaoyuan

PY - 2018/4/27

Y1 - 2018/4/27

N2 - Several radioligands targeting prostate-specific membrane antigen (PSMA) have been clinically introduced as a new class of radiotheranostics for the treatment of prostate cancer. Among them, (((R)-1-carboxy-2-mcercaptoethyl)carbamoyl)-L-glutamic acid (MCG) has been successfully labeled with radioisotopes for prostate cancer imaging. The aim of this study is to conjugate MCG with an albumin binding moiety to further improve the in vivo pharmacokinetics. Methods: MCG was conjugated with an Evans blue (EB) derivative for albumin binding and a DOTA chelator. PSMA positive (PC3-PIP) and PSMA negative (PC3) cells were used for both in vitro and in vivo studies. Longitudinal PET imaging was performed at 1, 4, 24, and 48 h post injection to evaluate the biodistribution and tumor uptake of 86Y-DOTA-EB-MCG. DOTA-EB-MCG was also labeled with 90Y for radionuclide therapy. Besides tumor growth measurement, tumor response to escalating therapeutic doses were also evaluated by immunohistochemistry and fluorescence microscopy. Results: Based on quantification from 86Y-DOTA-EB-MCG PET images, the tracer uptake in PC3-PIP tumors increased from 22.33 ± 2.39 %ID/g at 1 h post-injection (p.i.), to the peak of 40.40 ± 4.79 %ID/g at 24 h p.i. Administration of 7.4 MBq of 90Y-DOTA-EB-MCG resulted in significant regression of tumor growth in PSMA positive xenografts. No apparent toxicity or body weight loss was observed in all treated mice. Conclusion: Modification of MCG with an Evans blue derivative resulted in a highly efficient prostate cancer targeting agent (EB-MCG), which showed great potential in prostate cancer treatment after being labeled with therapeutic radioisotopes.

AB - Several radioligands targeting prostate-specific membrane antigen (PSMA) have been clinically introduced as a new class of radiotheranostics for the treatment of prostate cancer. Among them, (((R)-1-carboxy-2-mcercaptoethyl)carbamoyl)-L-glutamic acid (MCG) has been successfully labeled with radioisotopes for prostate cancer imaging. The aim of this study is to conjugate MCG with an albumin binding moiety to further improve the in vivo pharmacokinetics. Methods: MCG was conjugated with an Evans blue (EB) derivative for albumin binding and a DOTA chelator. PSMA positive (PC3-PIP) and PSMA negative (PC3) cells were used for both in vitro and in vivo studies. Longitudinal PET imaging was performed at 1, 4, 24, and 48 h post injection to evaluate the biodistribution and tumor uptake of 86Y-DOTA-EB-MCG. DOTA-EB-MCG was also labeled with 90Y for radionuclide therapy. Besides tumor growth measurement, tumor response to escalating therapeutic doses were also evaluated by immunohistochemistry and fluorescence microscopy. Results: Based on quantification from 86Y-DOTA-EB-MCG PET images, the tracer uptake in PC3-PIP tumors increased from 22.33 ± 2.39 %ID/g at 1 h post-injection (p.i.), to the peak of 40.40 ± 4.79 %ID/g at 24 h p.i. Administration of 7.4 MBq of 90Y-DOTA-EB-MCG resulted in significant regression of tumor growth in PSMA positive xenografts. No apparent toxicity or body weight loss was observed in all treated mice. Conclusion: Modification of MCG with an Evans blue derivative resulted in a highly efficient prostate cancer targeting agent (EB-MCG), which showed great potential in prostate cancer treatment after being labeled with therapeutic radioisotopes.

UR - http://www.scopus.com/inward/record.url?scp=85048141816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048141816&partnerID=8YFLogxK

U2 - 10.1021/acs.bioconjchem.8b00292

DO - 10.1021/acs.bioconjchem.8b00292

M3 - Article

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

ER -